Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Assets Average: 2013-2025

Historic Assets Average for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $290.9 million.

  • Enanta Pharmaceuticals' Assets Average fell 24.98% to $290.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $290.9 million, marking a year-over-year decrease of 24.98%. This contributed to the annual value of $328.7 million for FY2025, which is 21.64% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Assets Average stood at $290.9 million for Q3 2025, which was down 6.77% from $312.0 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' 5-year Assets Average high stood at $478.7 million for Q3 2023, and its period low was $290.9 million during Q3 2025.
  • Moreover, its 3-year median value for Assets Average was $387.7 million (2024), whereas its average is $380.7 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Assets Average rose by 25.88% in 2023, and later decreased by 24.98% in 2025.
  • Enanta Pharmaceuticals' Assets Average (Quarterly) stood at $439.7 million in 2021, then dropped by 17.79% to $361.5 million in 2022, then rose by 23.21% to $445.4 million in 2023, then declined by 18.58% to $362.6 million in 2024, then dropped by 24.98% to $290.9 million in 2025.
  • Its Assets Average was $290.9 million in Q3 2025, compared to $312.0 million in Q2 2025 and $335.8 million in Q1 2025.